RASSF1A gene promoter methylation has also been reported to confer poorer survival in surgically treated NSCLC [15], breast cancer [19], [33], stage I and II lung cancer [38] and Wilms' tumor [35]. This evidence concerns the gene RASSF1 and Nephroblastoma.